Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

Pages

15 results
12:00 AM, Jul 29, 2013  |  BC Week In Review | Clinical News  |  Clinical Results

DexaSite dexamethasone: Phase III data

U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus
patients achieving a disease severity score of 0 points at day 15 was 8.4% for AzaSite Plus
5.8% for DexaSite, 5.3% for AzaSite and 4.9% for DuraSite vehicle. InSite said that AzaSite Plus and …
12:00 AM, Jul 29, 2013  |  BC Week In Review | Clinical News  |  Clinical Results

AzaSite Plus: Phase III data

U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus
patients achieving a disease severity score of 0 points at day 15 was 8.4% for AzaSite Plus
5.8% for DexaSite, 5.3% for AzaSite and 4.9% for DuraSite vehicle. InSite said that AzaSite Plus and …
12:00 AM, Sep 24, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

DexaSite dexamethasone: Completed Phase III enrollment

completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus
and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 …
days. InSite has an SPA from FDA for DOUBle. AzaSite Plus, a combination of azithromycin antibiotic and …
12:00 AM, Sep 24, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

AzaSite Plus: Completed Phase III enrollment

completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus
and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 …
days. InSite has an SPA from FDA for DOUBle. AzaSite Plus has completed a Phase III trial …
12:00 AM, Aug 06, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

DexaSite dexamethasone: Phase III delayed

and clinical trials of BromSite . Details were not disclosed. The company is evaluating its AzaSite Plus
ISV-502 ) in DOUBle trial, while BromSite is in Phase III testing to treat ocular …
inflammation and pain in patients undergoing cataract surgery. AzaSite Plus is a combination of azithromycin antibiotic and …
12:00 AM, Nov 21, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

DexaSite dexamethasone: Phase III started

InSite began the double-blind, U.S. DOUBle Phase III trial in about 900 patients to evaluate AzaSite Plus
and DexaSite. Patients will receive AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 …
days. InSite has an SPA from FDA for DOUBle. AzaSite Plus, a combination of azithromycin antibiotic and …
12:00 AM, Nov 21, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

AzaSite Plus: Phase III started

InSite began the double-blind, U.S. DOUBle Phase III trial in about 900 patients to evaluate AzaSite Plus
and DexaSite. Patients will receive AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 …
days. InSite has an SPA from FDA for DOUBle. AzaSite Plus has completed a Phase III trial …
12:00 AM, May 30, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

DexaSite dexamethasone: SPA received

InSite received an SPA from FDA for the planned Phase III DOUBle trial to evaluate AzaSite Plus
and DexaSite in 900 patients. Patients will receive AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice …
daily for 14 days. AzaSite Plus, a combination of azithromycin antibiotic and dexamethasone corticosteroid in DuraSite, has …
12:00 AM, May 30, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

AzaSite Plus: SPA received

InSite received an SPA from FDA for the planned Phase III DOUBle trial to evaluate AzaSite Plus
and DexaSite in 900 patients. Patients will receive AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice …
daily for 14 days. AzaSite Plus has completed a Phase III trial to treat blepharoconjunctivitis and blepharitis …
12:00 AM, Apr 25, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

Dexamethasone: SPA submitted

InSite submitted an updated SPA to FDA for an upcoming Phase III trial to evaluate AzaSite Plus
DexaSite with the agency's 8 minor recommendations. Further details of the trial were not disclosed. AzaSite Plus

Pages